NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB - LARVOL DELTA

The subchronic intranasal administration of NeuroEPO improves motor recovery, the REDOX environment, and decreases depression-like behavior following severe traumatic brain injury in male rats (AES 2025) - "These results support NeuroEPO as a promising therapeutic strategy to mitigate secondary damage following severe TBI."

Preclinical • CNS Disorders • Depression • Psychiatry • Vascular Neurology • CAT

Subchronic Intranasal Administration of NeuroEPO Prevents Brain Atrophy and Long-Term Electrophysiological Changes after Severe Traumatic Brain Injury in Male Rats (AES 2025) - "These findings support NeuroEPO as a promising therapeutic strategy to prevent brain atrophy in key structures and hyperexcitability after a severe TBI."

Preclinical • Alzheimer's Disease • CNS Disorders • Epilepsy • Movement Disorders • Parkinson's Disease • Vascular Neurology

Subchronic intranasal administration of NeuroEPO reduces long term consequences of severe traumatic brain injury in male rats (Neuroscience 2025) - "In comparison to sham animals, NeuroEPO-treated TBI rats showed similar depressive like behavior (p=0.998), biochemical profiles (MDA: cortex: ipsi-, p=0.912; contra-, p=0.997; hippocampus: ipsi-, p0.999; contra-, p=0.991; hippocampus: ipsi- and contra-, p>0.999; amygdala: ipsi-, p=0.231; contra-, p=0.136; thalamus: p=0.998 and hypothalamus: p=0.751) and MRI-based structural measures (cortex: ipsi-, p=0.989; contra-, p=0.245; hippocampus: ipsi-, p=0.446; contra-, p=0.290; amygdala: ipsi-, p=0.997; contra-, p=0.882; thalamus: p=0.224; hypothalamus: p=0.966). These findings support NeuroEPO as a promising therapeutic intervention to reduce secondary damage and improve functional outcomes following severe TBI."

Preclinical • CNS Disorders • Vascular Neurology • CAT

Modulation of brain activity and tremor severity by NeuroEpo in Parkinson's patients with varying tremor amplitudes. (PubMed, Front Neurol) - "Customized treatment approaches incorporating tremor amplitude may improve therapeutic benefit and patient well-being. Future research should follow up on the long-term psychosocial effects of combined interventions."

Journal • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

NeuroEPO plus (NeuralCIM®) in Alzheimer's disease: Post-trial observational follow-up study. (PubMed, J Alzheimers Dis) - "The results for secondary outcomes showed statistically significant differences.ConclusionsSubjects who continued or started treatment with neuroEPO plus stabilized or slowed down the progression of the disease. These results and the method of drug administration, make neuroEPO plus an attractive option to consider for Alzheimer's disease patients."

Journal • Alzheimer's Disease • CNS Disorders • Psychiatry

Bayesian predictive probability for binary outcomes in neurodegenerative diseases. (PubMed, J Alzheimers Dis) - "Bayesian predictive probability is a valuable tool for decision-making in rare diseases, particularly when alternative treatments are limited or ineffective, or when baseline heterogeneity affects outcomes unevenly. This approach enhances interim evaluations by incorporating historical or non-informative priors, allowing for more accurate and efficient trial designs."

Journal • Alzheimer's Disease • Ataxia • CNS Disorders • Movement Disorders • Rare Diseases

Subchronic Intranasal Administration of NeuroEPO Reduces Long-Term Consequences of Severe Traumatic Brain Injury in Male Rats. (PubMed, Antioxidants (Basel)) - "Levels of malondialdehyde and catalase as well as the volume of brain structures of this group were like the Sham+vehicle group. These findings support the potential of NeuroEPO as a therapeutic agent to reduce long-term consequences of TBI."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry • Vascular Neurology • CAT

NeuroEPO plus (NeuralCIM) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial. (PubMed, Alzheimers Res Ther) - "Among participants with mild-moderate Alzheimer's disease clinical syndrome, neuroEPO plus improved the cognitive evaluation at 48 weeks, with a very good safety profile. Larger trials are warranted to determine the efficacy and safety of neuroEPO plus in Alzheimer's disease."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Inflammation

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

EEG as a mediator for the causal effect of NeuroEPO on motor performance and cognition in Parkinson (OHBM 2023) - "This study showed that the causal effect of NeuroEPO on cognitive and motor outcomes is mediated by qEEG(as a proxy of brain function). These results demonstrate the potential of qEEG as a tool for detecting the interventional effect of the drugs in PD patients."

Ataxia • CNS Disorders • Parkinson's Disease

EEG as a mediator for the causal effect of NeuroEPO on motor performance and cognition in Parkinson (OHBM 2023) - "This study showed that the causal effect of NeuroEPO on cognitive and motor outcomes is mediated by qEEG(as a proxy of brain function). These results demonstrate the potential of qEEG as a tool for detecting the interventional effect of the drugs in PD patients."

Ataxia • CNS Disorders • Parkinson's Disease

NEUROEPO IN NEURODEGENERATIVE DISORDERS (ADPD 2023) - "No serious adverse events related with NeuroEPO were reported. Conclusions NeuroEPO improved clinical outcomes with a good safety profile in patients with SCA2, PD and mild-to-moderate Alzheimer's clinical syndrome."

Alzheimer's Disease • Ataxia • CNS Disorders • Movement Disorders • Parkinson's Disease

Sensitive Analysis of Recombinant Human Erythropoietin Glycopeptides by On-Line Phenylboronic Acid Solid-Phase Extraction Capillary Electrophoresis Mass Spectrometry. (PubMed, J Proteome Res) - "Finally, the established method was used to analyze two rhEPO products (EPOCIM and NeuroEPO plus), demonstrating its applicability in biopharmaceutical analysis. The sensitivity of the proposed PBA-SPE-CE-MS method improves the existing CE-MS methodologies for glycopeptide analysis and shows a great potential in glycoprotein analysis to deeply characterize protein glycosites even at low concentrations of the protein digest."

Journal

A unique erythropoietin dosage induces the recovery of Long-Term synaptic Potentiation in fimbria-fornix lesioned rats. (PubMed, Brain Res) - "Restoring LTP by EPO might be a potential tool for the treatment of memory disturbing diseases like Alzheimeŕs disease. Ongoing clinical trials are evaluating a potential therapeutic effect of low sialic acid-EPO (NeuroEPO) on degenerative diseases."

Journal • Preclinical • Cognitive Disorders

The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity. (PubMed, Front Neurosci) - P1/2 | "A combined mediation model showed that 66% of the total effect of the cognitive improvement was mediated by qEEG (p = 0.0001), with the remaining direct effect between dose and Cognition (p = 0.002), due to other causes. These results suggest that Neuroepo has a positive influence on Cognition in PD patients and that a large portion of this effect is mediated by brain mechanisms reflected in qEEG."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study. (PubMed, Mov Disord) - "This study demonstrated the safety and tolerability of NeuroEPO in SCA2 patients after 6 months of treatments and suggested a small clinical effect of this drug on motor and cognitive abnormalities, but confirmatory studies are warranted."

Journal • Ataxia • CNS Disorders • Movement Disorders • Parkinson's Disease

NEUROEPO IN MILD-TO-MODERATE ALZHEIMER’S CLINICAL SYNDROME. PHASE 2-3 CONTROLLED CLINICAL TRIAL (ADPD 2022) - "Overall NeuroEPO significantly improved clinical outcomes with a good safety profile in patients with mild-to-moderate Alzheimer’s clinical syndrome."

Clinical • P2/3 data • Alzheimer's Disease • CNS Disorders • Immunology

Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis. (PubMed, J Pharm Biomed Anal) - "Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products. The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases."

Journal • CNS Disorders